8194 Life
- 3955
- 00.00%
Life News
Goldman Sachs Adjusts Life Time Group Holdings Price Target to $15 From $12, Maintains Neutral Rating
Goldman Sachs Maintains Neutral on Life Time Group Hldgs, Raises Price Target to $15
Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE), COMPASS Pathways (CMPS) and Olema Pharmaceuticals (OLMA)
Achieve Life Sciences (ACHV) Receives a Buy From Maxim Group
RBC Capital Maintains Market Outperform on Life Time Group Hldgs, Raises Price Target to $21
RBC Lifts Price Target on Life Time Group Holdings to $21 From $20, Maintains Outperform Rating
Morgan Stanley Keeps Their Hold Rating on Life Time Group Holdings (LTH)
Credit Suisse Lifts Price Target on Swiss Life, Maintains Neutral Recommendation
The Latest Analyst Ratings for ATAI Life Sciences
Credit Suisse Maintains Outperform on ATAI Life Sciences, Lowers Price Target to $9
EF Hutton Sticks to Their Buy Rating for ATAI Life Sciences (ATAI)
EF Hutton Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target
Autonomous Research Lifts Price Target on Swiss Life, Maintains Underperform Recommendation
H.C. Wainwright Sticks to Their Buy Rating for ATyr Pharma (LIFE)
Benchmark Co. Remains a Buy on Life Storage (LSI)
Morgan Stanley Remains a Hold on American Equity Investment Life (AEL)
Morgan Stanley Adjusts Price Target on Globe Life to $133 From $132, Maintains Underweight Rating
AlphaValue/Baader Europe Lowers Price Target on Swiss Life, Maintains Add Recommendation
UOB Kay Hian Upgrades Parkway Life REIT to Buy From Hold, Adjusts Price Target to SG$4.49 From SG$4.43
Barclays Keeps Their Buy Rating on Swiss Life Holding AG (SWSDF)
Analysis
Price Target
No Data
